Once-daily mesalamine granules for ulcerative colitis.

about

Mesalamine in the treatment and maintenance of remission of ulcerative colitis Drug development in inflammatory bowel disease: the role of the FDA.Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.

P2860

Q26865546-67244AED-2705-4DBD-BC05-5FCEAD6103DD Q37864253-2E108EBD-02A3-4513-A240-5F8BEE109086 Q37995669-1A03FBAA-4588-4750-B25A-08EBC2C6BB10

P2860

Once-daily mesalamine granules for ulcerative colitis.

Item

http://www.wikidata.org/entity/Q42995730

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Once-daily mesalamine granules for ulcerative colitis.

@en

Once-daily mesalamine granules for ulcerative colitis.

@nl

type

Item

label

Once-daily mesalamine granules for ulcerative colitis.

@en

Once-daily mesalamine granules for ulcerative colitis.

@nl

prefLabel

Once-daily mesalamine granules for ulcerative colitis.

@en

Once-daily mesalamine granules for ulcerative colitis.

@nl

P1476

Once-daily mesalamine granules for ulcerative colitis.

@en

P2093

Alan C Moss

http://www.w3.org/2001/XMLSchema#string

Awais Ahmed

http://www.w3.org/2001/XMLSchema#string

Garrett Lawlor

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

Interstitial nephritis from mesalazine: case report and literature review.

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.

PPARgamma as a new therapeutic target in inflammatory bowel diseases

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma

Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.

The risks and the benefits of mesalazine as a treatment for ulcerative colitis.

P304

521-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.10.22

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20594123

http://www.w3.org/2001/XMLSchema#string

Once-daily mesalamine granules for ulcerative colitis.

about

P2860

P2860

Once-daily mesalamine granules for ulcerative colitis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698